1Department of Obstetrics and Gynecology, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan.
Department of Obstetrics and Gynecology, Tokai University School of Medicine, Isehara, Japan.
Int J Clin Oncol. 2019 Jan;24(1):1-19. doi: 10.1007/s10147-018-1351-y. Epub 2018 Oct 5.
The Japan Society of Gynecologic Oncology (JSGO) Guidelines 2017 for the Treatment of Uterine Cervical Cancer are for the purpose of providing standard treatment strategies for cervical cancer, indicating treatment methods currently considered appropriate for cervical cancer, minimizing variances in treatment methods among institutions, improving the safety of treatment and prognosis of diseases, reducing the economic and psychosomatic burden of patients by promoting performance of appropriate treatment, and enhancing mutual understanding between patients and healthcare professionals. The guidelines were prepared through consensus of the JSGO Guideline Committee, based on careful review of evidence gathered through the literature searches and in view of the medical health insurance system and actual clinical practice situations in Japan. The guidelines comprise eight chapters and five algorithms. The main features of the 2017 revision are as follows: (1) evidence was collected using a search formula and with cooperation of the Japan Library Association. The bibliographical search formula was placed at the end of the book; (2) regarding clinical questions (CQs) where evidence or clinical inspection in Japan was lacking, opinions of the Guidelines Committee were described as "proposals for future directions"; (3) cervical intraepithelial neoplasia (CIN) 3 and adenocarcinoma in situ (AIS) were treated as a cervical precancerous lesion; (4) the CQs of endoscopic surgery, radical trachelectomy, and sentinel node biopsy were newly added in Chapter 3, "primary treatment for stage IB-II cervical cancer"; and (5) the CQ about hormone replacement therapy after cancer treatment was newly established. Each recommendation is accompanied by a classification of recommendation categories based on the consensus reached by the Guideline Committee members. Here, we present the English version of the JSGO Guidelines 2017 for the Treatment of Uterine Cervical Cancer.
日本妇科肿瘤学会（JSGO）2017 年子宫颈癌治疗指南旨在为宫颈癌提供标准治疗策略，指明目前认为适合宫颈癌的治疗方法，减少医疗机构之间治疗方法的差异，提高治疗安全性和疾病预后，通过促进适当的治疗来减轻患者的经济和心理负担，并增进患者与医疗保健专业人员之间的相互理解。该指南是由 JSGO 指南委员会通过共识制定的，基于对通过文献检索收集的证据进行仔细审查，并考虑到日本的医疗保险制度和实际临床实践情况。该指南包括八个章节和五个算法。2017 年修订的主要特点如下：（1）使用搜索公式和日本图书馆协会的合作收集证据。书目搜索公式放在书的末尾；（2）对于在日本缺乏证据或临床检查的临床问题（CQs），指南委员会的意见被描述为“未来方向的建议”；（3）宫颈上皮内瘤变（CIN）3 和原位腺癌（AIS）被视为宫颈癌前病变；（4）第 3 章“IB-II 期宫颈癌的初始治疗”中新增加了内镜手术、根治性宫颈切除术和前哨淋巴结活检的 CQ；（5）新建立了癌症治疗后激素替代治疗的 CQ。每个推荐都附有一个基于指南委员会成员达成共识的推荐类别分类。在这里，我们呈现日本妇科肿瘤学会 2017 年子宫颈癌治疗指南的英文版本。
Zotero 插件